Cargando…

Pirfenidone facilitates immune infiltration and enhances the antitumor efficacy of PD-L1 blockade in mice

Idiopathic pulmonary fibrosis (IPF) patients have a high risk of developing lung cancer, with few treatment options available. Pirfenidone, an antifibrotic agent approved for the treatment of IPF, has been demonstrated to suppress the TGFβ signaling and modulate the expression of immune-related gene...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qin, Wan, Zou, Jun, Huang, Yongbiao, Liu, Chaofan, Kang, Yalin, Han, Hu, Tang, Yang, Li, Long, Liu, Bo, Zhao, Weiheng, Yuan, Xianglin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7781712/ https://www.ncbi.nlm.nih.gov/pubmed/33457101 http://dx.doi.org/10.1080/2162402X.2020.1824631

Ejemplares similares

Nintedanib enhances the efficacy of PD-L1 blockade by upregulating MHC-I and PD-L1 expression in tumor cells
por: Tu, Jingyao, et al.
Publicado: (2022)

Progress and prospects of nanozymes for enhanced antitumor therapy
por: Yu, Yulong, et al.
Publicado: (2022)

Tasquinimod modulates tumor-infiltrating myeloid cells and improves the antitumor immune response to PD-L1 blockade in bladder cancer
por: Nakhlé, Jessica, et al.
Publicado: (2016)

Combining radiation and the ATR inhibitor berzosertib activates STING signaling and enhances immunotherapy via inhibiting SHP1 function in colorectal cancer
por: Liu, Chaofan, et al.
Publicado: (2023)

PD-1 blockade in combination with zoledronic acid to enhance the antitumor efficacy in the breast cancer mouse model
por: Li, Yuan, et al.
Publicado: (2018)

Inhibition of galectin‐3 augments the antitumor efficacy of PD‐L1 blockade in non‐small‐cell lung cancer
por: Zhang, Hongxin, et al.
Publicado: (2021)

Pan-TGFβ inhibition by SAR439459 relieves immunosuppression and improves antitumor efficacy of PD-1 blockade
por: Greco, Rita, et al.
Publicado: (2020)

CD73 and PD-L1 dual blockade amplifies antitumor efficacy of SBRT in murine PDAC models
por: Ye, Jian, et al.
Publicado: (2023)

Ibrutinib Inhibits BTK Signaling in Tumor-Infiltrated B Cells and Amplifies Antitumor Immunity by PD-1 Checkpoint Blockade for Metastatic Prostate Cancer
por: Deng, Gengguo, et al.
Publicado: (2023)

Progress and perspectives of platinum nanozyme in cancer therapy
por: Wang, Xi, et al.
Publicado: (2022)

Intra-tumoral infiltration of adipocyte facilitates the activation of antitumor immune response in pancreatic ductal adenocarcinoma
por: Liu, Xiaomeng, et al.
Publicado: (2022)

Efficacy and safety of pirfenidone for idiopathic pulmonary fibrosis
por: Takeda, Yoshito, et al.
Publicado: (2014)

PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
por: Xu-Monette, Zijun Y., et al.
Publicado: (2017)

Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors
por: Yi, Ming, et al.
Publicado: (2018)

Pirfenidone: is it tolerable?
por: Lara, Abigail, et al.
Publicado: (2016)

TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM
por: Hung, Alice L., et al.
Publicado: (2018)

Blockade of trans PD-L1 interaction with CD80 augments antitumor immunity
por: Zhang, Yuankun, et al.
Publicado: (2023)

Mechanistic insight of predictive biomarkers for antitumor PD-1/PD-L1 blockade: A paradigm shift towards immunome evaluation
por: You, Wenjie, et al.
Publicado: (2020)

Potential Biomarkers for the Efficacy of PD-1-PD-L Blockade in Cancer
por: Grecea, Miruna, et al.
Publicado: (2021)

Accumulation of dysfunctional tumor-infiltrating PD-1+ DCs links PD-1/PD-L1 blockade immunotherapeutic response in cervical cancer
por: Wang, Yu-meng, et al.
Publicado: (2022)

Abrine Elicits Liver Carcinoma Immunity and Enhances Antitumor Efficacy of Immune Checkpoint Blockade by Modulating PD-L1 Signaling
por: Zhang, Shaowu
Publicado: (2022)

Tumor-associated neutrophils suppress antitumor immunity of NK cells through the PD-L1/PD-1 axis
por: Sun, Rui, et al.
Publicado: (2020)

Combination of immune checkpoint blockade and targeted gene regulation of angiogenesis for facilitating antitumor immunotherapy
por: Zhan, Jing, et al.
Publicado: (2023)

Hyperbaric oxygen facilitates teniposide-induced cGAS-STING activation to enhance the antitumor efficacy of PD-1 antibody in HCC
por: Li, Kun, et al.
Publicado: (2022)

Case Report: Pirfenidone in the Treatment of Post-COVID-19 Pulmonary Fibrosis
por: Zhou, Xianglin, et al.
Publicado: (2022)

Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials
por: Zhao, Bin, et al.
Publicado: (2020)

PARP Inhibitor Upregulates PD-L1 Expression and Provides a New Combination Therapy in Pancreatic Cancer
por: Wang, Yali, et al.
Publicado: (2021)

MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment
por: Fang, Douglas D., et al.
Publicado: (2019)

Anlotinib Induces a T Cell–Inflamed Tumor Microenvironment by Facilitating Vessel Normalization and Enhances the Efficacy of PD-1 Checkpoint Blockade in Neuroblastoma
por: Su, Yudong, et al.
Publicado: (2022)

Antitumor efficacy of combined CTLA4/PD-1 blockade without intestinal inflammation is achieved by elimination of FcγR interactions
por: Bauché, David, et al.
Publicado: (2020)

Fusobacterium nucleatum enhances the efficacy of PD-L1 blockade in colorectal cancer
por: Gao, Yaohui, et al.
Publicado: (2021)

Integrative Analysis Constructs an Extracellular Matrix-Associated Gene Signature for the Prediction of Survival and Tumor Immunity in Lung Adenocarcinoma
por: Xiao, Lingyan, et al.
Publicado: (2022)

Characterization of the SARS-CoV-2 co-receptor NRP1 expression profiles in healthy people and cancer patients: Implication for susceptibility to COVID-19 disease and potential therapeutic strategy
por: Huang, Yongbiao, et al.
Publicado: (2022)

Comprehensive Pan-Cancer Analyses of Immunogenic Cell Death as a Biomarker in Predicting Prognosis and Therapeutic Response
por: Wang, Yuan, et al.
Publicado: (2022)

Efficacy and adverse events of pirfenidone in treating idiopathic pulmonary fibrosis
por: Ren, Hui, et al.
Publicado: (2017)

Real-world experiences: Efficacy and tolerability of pirfenidone in clinical practice
por: Fang, Chuling, et al.
Publicado: (2020)

Protective efficacy of pirfenidone in rats with pulmonary fibrosis induced by bleomycin
por: Demirkol, Barış, et al.
Publicado: (2023)

From rough to precise: PD-L1 evaluation for predicting the efficacy of PD-1/PD-L1 blockades
por: Zhao, Xuan, et al.
Publicado: (2022)

IFNAR blockade synergizes with oncolytic VSV to prevent virus-mediated PD-L1 expression and promote antitumor T cell activity
por: El-Sayes, Nader, et al.
Publicado: (2022)

TNF blockade uncouples toxicity from antitumor efficacy induced with CD40 chemoimmunotherapy
por: Stone, Meredith L., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_dr1nlmaeg5j108rop3o9q2ap0r